TheranosticTrials.org

Clinical Trial · NCT07557225

18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors

Overview

The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 18F-T2 in PET/CT imaging in participants with solid tumors. It will also assess the safety, tolerability and radiation dosimetry of 18F-T2.

Sponsor

Peking University First Hospital

Phase

N/A

Contacts

Keting Tong (CONTACT)

1910301229@pku.edu.cn

+86 010-83575252

Meng Liu (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT07557225

Drug / Compound

T2

Isotope(s):
Target(s):
  • CAIX
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Have the capacity to understand the study and be willing and able to comply with all protocol requirements.
  • Male or female ≥18 years of age at time of consent.
  • All participants must meet the following criteria:
  • Participants with histologically confirmed or suspected tumors of the following types, but not limited to:Clear Cell Renal Cell Cancer; Urothelial Carcinoma; Colorectal Cancer; Cervical Cancer; Ovarian Cancer; Head and Neck Cancer; Hepatocellular Carcinoma; Cholangiocarcinoma; Non Small Cell Lung Cancer; Small Cell Lung Cancer; Breast Cancer; Pancreatic Cancer; Endometrial Cancer; Von Hippel Lindau Disease.
  • Written and voluntarily given Informed Consent.

Exclusion

  • Have a mental impairment that may compromise the ability to give Informed Consent and comply with the requirements of the study.
  • Be a female who is pregnant or breastfeeding.
  • Participants will be excluded from participation in the study if one or more of the following criteria are met:
  • Have any serious non-malignant disease (e.g., psychiatric, infectious, autoimmune or metabolic) that may interfere with the objectives of the study or with the safety or compliance of the participant, as judged by the Investigator.